Stakeholders’ experiences with a clinician-led access programme linking evidence generation and reimbursement for precision cancer treatments: the drug access protocol in the Netherlands
DOI:
https://doi.org/10.2340/1651-226X.2026.45000Keywords:
health technology assessment; reimbursement mechanism; medical oncologyAbstract
Background and purpose: In the current landscape of tumour-agnostic oncology drugs receiving European Medicines Agency (EMA) authorisation, Health Technology Assessment (HTA) bodies face challenges in assessing these innovative drugs. Due to these products’ non-randomised, single-arm nature, uncertainty exists regarding their real-world benefit. In the Netherlands, the Drug Access Protocol (DAP), a programme developed by oncologists, insurers and the healthcare public institute, aims to provide an innovative solution to address this uncertainty. This study aims to investigate the key characteristics, enablers and challenges of the programme by exploring stakeholders’ perceptions.
Patient/material and methods: A qualitative, semi-structured interview study was conducted. A supporting interview guide was drafted using available literature and a flowchart figure to illustrate the process. Interviews were conducted with market authorisation holders (MAHs) who participated in the programme, the insurer, the DAP study management and the DAP’s governance committee. Recorded interviews were transcribed, pseudonymised and subsequently coded using NVivo software. Inductive thematic analysis was used to identify common themes, enablers and challenges for participating in the programme.
Results: In total, eight organisations were interviewed. Although MAHs indicated several enablers (e.g. providing patient access, collecting real-world data), several challenges (e.g. the lack of transparency) lead to questions regarding the feasibility of the programme. Health insurers acknowledge these outcomes and expect products that obtain regular reimbursement to serve as an example.
Interpretation: As the Drug Access Protocol may be a promising solution to mitigate uncertainties for healthcare decision-makers, implementation challenges can hamper its feasibility. Addressing these challenges could realise the potential of such programmes.
Downloads
References
IKNL. Dure geneesmiddelen, online magazine. Integraal Kankercent. Ned. IKNL; [cited 2025 Jan 30]. Available from: https://iknl.nl/online-magazine-dure-geneesmiddelen
Hofmarcher, T., C. Berchet and G. Dedet (2024), “Access to oncology medicines in EU and OECD countries”, OECD Health Working Papers, No. 170, OECD Publishing, Paris, https://doi.org/10.1787/c263c014-en DOI: https://doi.org/10.1787/c263c014-en
Rome BN, Egilman AC, Kesselheim AS. Trends in prescription drug launch prices, 2008–2021. JAMA. 2022;327:2145–7.
https://doi.org/10.1001/jama.2022.5542 DOI: https://doi.org/10.1001/jama.2022.5542
Devi S. Rising costs of cancer medicines. Lancet Oncol. 2024;25:1262.
https://doi.org/10.1016/S1470-2045(24)00516-3 DOI: https://doi.org/10.1016/S1470-2045(24)00516-3
Brinkhuis F, Goettsch WG, Mantel-Teeuwisse AK, Bloem LT. High cost oncology drugs without proof of added benefit are burdening health systems. BMJ. 2024;384:q511.
https://doi.org/10.1136/bmj.q511 DOI: https://doi.org/10.1136/bmj.q511
Post HC, Schutte T, van Oijen MGH, van Laarhoven HWM, Hollak CEM. Time to reimbursement of novel anticancer drugs in Europe: a case study of seven European countries. ESMO Open. 2023;8:101208.
https://doi.org/10.1016/j.esmoop.2023.101208 DOI: https://doi.org/10.1016/j.esmoop.2023.101208
Exploring the feasibility of monitoring access to novel medicines. OECD; 2023 [cited 2025 Jan 27]. Available from: https://www.oecd.org/en/publications/exploring-the-feasibility-of-monitoring-access-to-novel-medicines_8c1d16c4-en.html
Callenbach MHE, Vreman RA, Mantel-Teeuwisse AK, Goettsch WG. When reality does not meet expectations – experiences and perceived attitudes of Dutch stakeholders regarding payment and reimbursement models for high-priced hospital drugs. Int J Environ Res Public Health. 2022;20:340.
https://doi.org/10.3390/ijerph20010340 DOI: https://doi.org/10.3390/ijerph20010340
Michelsen S, Nachi S, Van Dyck W, Simoens S, Huys I. Barriers and opportunities for implementation of outcome-based spread payments for high-cost, one-shot curative therapies. Front Pharmacol. 2020;11:594446.
https://doi.org/10.3389/fphar.2020.594446 DOI: https://doi.org/10.3389/fphar.2020.594446
Zampirolli Dias C, Godman B, Gargano L, Azevedo P, Garcia M, Cazarim M, et al. Integrative review of managed entry agreements: chances and limitations. PharmacoEconomics. 2020;38:1165–85.
https://doi.org/10.1007/s40273-020-00943-1 DOI: https://doi.org/10.1007/s40273-020-00943-1
Neuvel H. DRUG Access Protocol gestart. Ned Ver Voor Med Oncol. NVMO; 2021 [cited 2025 Jan 24]. Available from: https://www.nvmo.org/2021/01/drug-access-protocol-gestart/
Zeverijna LJ, Barjesteh van Waalwijk van Doorn-Khosrovanid S, van Royd AAMGP, Timmerse L, ∙ Trane THL, de Boere JE. Harmonising patient-access programmes: the Dutch DRUG Access Protocol platform. Lancet Oncol. 2022;23:198–201.
https://doi.org/10.1016/S1470-2045(21)00707-5 DOI: https://doi.org/10.1016/S1470-2045(21)00707-5
van Waalwijk van Doorn-Khosrovani SB, Zeverijn LJ, Voest EE. The DRUG Access Protocol: access inequality and European harmonisation – authors’ reply. Lancet Oncol. 2022;23:e203.
https://doi.org/10.1016/S1470-2045(22)00210-8 DOI: https://doi.org/10.1016/S1470-2045(22)00210-8
Polak TB, Cucchi DGJ, van Rosmalen J, Groot CAU. The DRUG Access Protocol: access inequality and European harmonisation. Lancet Oncol. 2022;23:e202.
https://doi.org/10.1016/S1470-2045(22)00098-5 DOI: https://doi.org/10.1016/S1470-2045(22)00098-5
Nederlandse Vereniging voor Medische Oncologie (NVMO). Procedure Drug Access Protocol. [cited 2025 Jan 29]. Available from: https://www.nvmo.org/wp-content/uploads/2023/09/Drug-Access-Protocol-NVMO-NVALT-20230614-definitief.pdf
Ministerie van Volksgezondheid W en S. Beoordeling stand van de wetenschap en praktijk 2023 – Publicatie – Zorginstituut Nederland. 2023 [cited 2025 Jan 27]. Available from: https://www.zorginstituutnederland.nl/publicaties/publicatie/2023/04/11/beoordeling-swp-2023
Danen A. We hebben de lat hoog gelegd. Med Oncol. 2021;24:34–6.
https://doi.org/10.24078/onco.2021.5.127336 DOI: https://doi.org/10.24078/onco.2021.5.127336
Nederlandse Vereniging voor Medische Oncologie (NVMO). Over de adviezen. [cited 2025 Jan 27]. Available from: https://www.nvmo.org/over-de-adviezen/
Corro Ramos I, Qendri V, Al M. Beyond hazard ratios: appropriate statistical methods for quantifying the clinical effectiveness of immune-oncology therapies – the example of the Netherlands. BMC Med Res Methodol. 2024;24:260.
https://doi.org/10.1186/s12874-024-02373-5 DOI: https://doi.org/10.1186/s12874-024-02373-5
Xandera NSH, Leenemana B, Dingemansc A-MC, Fietsd WE, de Jonge WK, Uyl NEM. Using non-randomized trials to assess the clinical benefit of systemic anti-cancer treatments: viable or not? Eur J Cancer. 2024;209:114262.
https://doi.org/10.1016/j.ejca.2024.114262 DOI: https://doi.org/10.1016/j.ejca.2024.114262
DRUP and DAP Study Team. DRUP & DAP Newsletter October 2024. [cited 2025 Jan 17]. Available from: https://mailchi.mp/25747bfa1632/drup-dap-newsupdate-85-mayjune-10347207?e=ed76b72196
Cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: prospective real-world data from the DRUG Access Protocol – The Lancet Regional Health – Europe. [cited 2025 Jan 20]. Available from: https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(24)00041-3/fulltext
Ministerie van Volksgezondheid W en S. Pakketadvies entrectinib en larotrectinib (Rozlytrek® en Vitrakvi®) voor de behandeling van volwassen en kinderen met solide tumoren (kanker) met NTRK-genfusie – Advies – Zorginstituut Nederland. 2023 [cited 2025 Jun 10]. Available from: https://www.zorginstituutnederland.nl/publicaties/adviezen/2023/07/27/pakketadvies-entrectinib-en-larotrectinib-rozlytrek-en-vitrakvi
Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3:77–101.
https://doi.org/10.1191/1478088706qp063oa DOI: https://doi.org/10.1191/1478088706qp063oa
Horizon Scan for Medicinal Products. National Health Care Institute; [cited 2025 Jun 13]. Available from: https://english.zorginstituutnederland.nl/international-network/horizon-scan-for-medicinal-products
Pauwels K, Huys I, Vogler S, Casteels M, Simoens S. Managed entry agreements for oncology drugs: lessons from the european experience to inform the future. Front Pharmacol. 2017;8.
https://doi.org/10.3389/fphar.2017.00171 DOI: https://doi.org/10.3389/fphar.2017.00171
Barjestehvan Waalwijk van Doorn-Khosrovani S, Timmers L, Pisters-van Roy A, Gijzen J, Blijlevens NMA, Bloemendal H. Manufacturers’ views on outcome-based agreements. J Mark Access Health Policy. 2021;9:1993593.
https://doi.org/10.1080/20016689.2021.1993593 DOI: https://doi.org/10.1080/20016689.2021.1993593
Farmer C, Barnish MS, Trigg LA, Hayward S, Shaw N, Crathorne L. An evaluation of managed access agreements in England based on stakeholder experience. Int J Technol Assess Health Care. 2023;39:e55.
https://doi.org/10.1017/S0266462323000478 DOI: https://doi.org/10.1017/S0266462323000478
Callenbach MHE, Schoenmakers D, Vreman RA, Vijgen S, Timmers L, Hollak CEM, et al. Illustrating the financial consequences of outcome-based payment models from a payers perspective: the case of autologous gene therapy Atidarsagene Autotemcel (Libmeldy®). Value Health. 2024;27:1046–57.
https://doi.org/10.1016/j.jval.2024.05.010 DOI: https://doi.org/10.1016/j.jval.2024.05.010
Hogervorst MA, van Hattem CC, Sonke GS, Mantel-Teeuwisse AK, Goettsch WG, Bloem LT. Healthcare decision-making for tumour-agnostic therapies in Europe: lessons learned. Drug Discov Today. 2024;29:104031.
https://doi.org/10.1016/j.drudis.2024.104031 DOI: https://doi.org/10.1016/j.drudis.2024.104031
Haj Mohammad SF, Timmer HJL, Zeverijnb LJ, Geurtsb BS, Spiekmanc IAC, Verkerk K, et al. The evolution of precision oncology: the ongoing impact of the Drug Rediscovery Protocol (DRUP). Acta Oncol. 2024;63:34885.
https://doi.org/10.2340/1651-226X.2024.34885 DOI: https://doi.org/10.2340/1651-226X.2024.34885
Kringelbach TM, ∙ Fagereng L, ∙ Haj Mohammad SF, ∙Verbeek F, Timmer HJL, Juslin T, et al. 197P PRIME-ROSE: merging clinical outcome data from DRUP-like clinical trials. Ann Oncol. 2024;35:S294–5.
https://doi.org/10.1016/j.annonc.2024.08.2202 DOI: https://doi.org/10.1016/j.annonc.2024.08.2202
van Waalwijk van Doorn-Khosrovani SB, Huisman AH, Timmer HJL, ∙ Verkerk K, ∙ Verbeek F, ∙ Fagereng L, et al. 1550P Addressing uncertainties of clinical value and improving access for newly authorised indications through DRUG-Access Protocol (DAP)-like platforms: joint collection and evaluation of real-world evidence. Ann Oncol. 2024;35:S943–4.
https://doi.org/10.1016/j.annonc.2024.08.1612 DOI: https://doi.org/10.1016/j.annonc.2024.08.1612
Bindels J, Ramaekers B, Corro Ramos I, Mohseninejad L, Knies S, Grutters J, et al. Use of value of information in healthcare decision making: exploring multiple perspectives. Pharmacoeconomics. 2016;34:315–22.
https://doi.org/10.1007/s40273-015-0346-z DOI: https://doi.org/10.1007/s40273-015-0346-z
Grimm SE, Pouwels X, Ramaekers BLT, van Ravesteyn NT, Sankatsing VDV, ∙ Janneke Grutters J, et al. Implementation barriers to value of information analysis in health technology decision making: results from a process evaluation. Value Health. 2021;24:1126–36.
https://doi.org/10.1016/j.jval.2021.03.013 DOI: https://doi.org/10.1016/j.jval.2021.03.013
Ministerie van Volksgezondheid W en S. Richtlijn voor het uitvoeren van economische evaluaties in de gezondheidszorg (versie 2024) – Publicatie – Zorginstituut Nederland. 2024 [cited 2025 Jan 30]. https://www.zorginstituutnederland.nl/publicaties/publicatie/2024/01/16/richtlijn-voor-het-uitvoeren-van-economische-evaluaties-in-de-gezondheidszorg
Tuffaha HW, Gordon LG, Scuffham PA. Value of information analysis in oncology: the value of evidence and evidence of value. J Oncol Pract. 2014;10:e55–62.
https://doi.org/10.1200/JOP.2013.001108 DOI: https://doi.org/10.1200/JOP.2013.001108
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2026 Christine Leopold, Atse H Huisman, Kevin J. G. M. Vlaar, Haiko J Bloemendal, Sahar Barjesteh van Waalwijk van Doorn-Khosrovani
This work is licensed under a Creative Commons Attribution 4.0 International License.
